Hepatitis B core antigen expression in hepatocytes reflects viral response to entecavir in chronic hepatitis B patients.
Hepatitis B core antigen expression in hepatocytes reflects viral response to entecavir in chronic hepatitis B patients.
复制标题
DOI：
10.5009/gnl.2013.7.4.462
复制
发表时间：
2013-07
期刊：
影响因子：
3.4
通讯作者：
Rim KS
中科院分区：
文献类型：
--
作者：
Lee JG;Hwang SG;Yoon H;Son MS;Kim DY;Yoo JH;Kim KI;Rim KS
乙型肝炎核心抗原是已知的病毒特异性T细胞的主要靶标，也反映了肝脏疾病的进展和病毒复制。乙型肝炎核心抗原在肝细胞中的表达导致组织学活性、病毒复制和免疫反应的改变。本研究的目的是评估乙型肝炎核心抗原表达的地形分布是否可以预测慢性乙型肝炎患者对恩替卡韦的病毒反应。我们招募了91例treatment-naïve慢性乙型肝炎患者。所有患者进行肝活检，并通过免疫组织化学评估乙型肝炎核心抗原的存在和模式。所有患者在肝活检后每天接受0.5 mg恩替卡韦。我们在抗病毒治疗的第3、6和12个月时检查病毒反应。91例患者中，64例（70.3%）有乙型肝炎核心抗原表达。亚细胞型以混合型为主（n= 48,75%）。在恩替卡韦治疗12个月后，乙肝核心抗原阴性组的病毒应答率明显高于乙肝核心抗原阳性组（分别为88.9%和54.7%,p=0.001）。乙型肝炎核心抗原阴性的慢性乙型肝炎患者对恩替卡韦治疗的反应优于乙型肝炎核心抗原阳性患者。
Hepatitis B core antigen is known to be a major target for virus-specific T cells and also reflects the progression of liver dissease and viral replication. Hepatitis B core antigen expression in hepatocytes leads to altered histological activity, viral replication, and immune response. The purpose of this study is to evaluate whether the topographical distribution of hepatitis B core antigen expression can predict the viral response to entecavir in patients with chronic hepatitis B. We enrolled 91 patients with treatment-naïve chronic hepatitis B. All the patients underwent liver biopsy, and the existence and pattern of hepatitis B core antigen evaluated by immunohistochemistry. All patients received 0.5 mg of entecavir daily following a liver biopsy. We checked the viral response at 3, 6, and 12 months during antiviral therapy. Of the 91 patients, 64 (70.3%) had hepatitis B core antigen expression. Of the subcellular patterns, the mixed type was dominant (n=48, 75%). The viral response was significantly higher in the hepatitis B core antigen-negative group than in the hepatitis B core antigen-positive group (88.9% and 54.7%, respectively; p=0.001) after 12 months of entecavir therapy. Chronic hepatitis B patients who are hepatitis B core antigen-negative have a better response to entecavir therapy than do hepatitis B core antigen-positive patients.
登录
查看更多内容
影响因子：
3.4
作者：
Son, Su Myung;Yoo, Jeong Hwan;Rim, Kyu Sung
通讯作者：
Rim, Kyu Sung
DOI：
10.1111/j.1440-1746.2006.04263.x
发表时间：
2006-06-01
影响因子：
4.1
作者：
Uzun, Yusuf;Bozkaya, Hakan;Uzunalimoglu, Ozden
通讯作者：
Uzunalimoglu, Ozden
DOI：
10.1073/pnas.0401771101
发表时间：
2004-04-27
影响因子：
11.1
作者：
Wieland, S;Thimme, R;Chisari, FV
通讯作者：
Chisari, FV
影响因子：
29.4
作者：
CHU, CM;YEH, CT;LIAW, YF
通讯作者：
LIAW, YF
影响因子：
5.4
作者：
Thimme, R;Wieland, S;Chisari, FV
通讯作者：
Chisari, FV